Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Income from Continuing Operations: 2015-2024

Historic Income from Continuing Operations for Seres Therapeutics (MCRB) over the last 10 years, with Dec 2024 value amounting to -$117.3 million.

  • Seres Therapeutics' Income from Continuing Operations rose 23.35% to -$21.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$101.2 million, marking a year-over-year increase of 18.79%. This contributed to the annual value of -$117.3 million for FY2024, which is 38.32% up from last year.
  • Latest data reveals that Seres Therapeutics reported Income from Continuing Operations of -$117.3 million as of FY2024, which was up 38.32% from -$190.3 million recorded in FY2023.
  • In the past 5 years, Seres Therapeutics' Income from Continuing Operations ranged from a high of -$64.5 million in FY2021 and a low of -$190.3 million during FY2023.
  • Over the past 3 years, Seres Therapeutics' median Income from Continuing Operations value was -$182.9 million (recorded in 2022), while the average stood at -$163.5 million.
  • As far as peak fluctuations go, Seres Therapeutics' Income from Continuing Operations crashed by 183.38% in 2022, and later skyrocketed by 38.32% in 2024.
  • Over the past 5 years, Seres Therapeutics' Income from Continuing Operations (Yearly) stood at -$90.1 million in 2020, then increased by 28.38% to -$64.5 million in 2021, then plummeted by 183.38% to -$182.9 million in 2022, then declined by 4.04% to -$190.3 million in 2023, then spiked by 38.32% to -$117.3 million in 2024.